Prescription Medicines
Dexidifen Tab. 400mg
- Product Category
- Analgesics, Antipyretics & Anti-inflammatory Medicines
- Active Ingredients
- Dexibuprofen D.C.
- Appearance
- A white, oblong, film-coated tablet.
- Reimbursement Code
- 648104320
01 / 02
1. Ingredient content
1 tablet
- Active ingredient: Dexibuprofen D.C. (in-house specification) --- 400mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Stearic acid, Opadry IIAMB White (88A180040), Opadry White (03B28796), low-substituted hydroxypropyl cellulose, colloidal silicon oxide
2. Effectiveness
1. Chronic polyarthritis, rheumatoid arthritis
2. Arthropathy
3. Ankylosing spondylitis
4. Painful swelling or inflammation after trauma or surgery
5. Aid in the treatment of infections accompanied by inflammation, pain, and fever
3. Dosage and dosage
Adults: Orally administer 400 mg at a time as dexibuprofen, 2 to 3 times a day.
However, the daily dose of dexibuprofen should not exceed 1,200 mg.
4. Precautions for use
1. Warning
1) If a person who regularly drinks more than 3 cups of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about the signs and/or symptoms of serious cardiovascular toxicity and the measures to be taken if these symptoms occur.
Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischemic heart disease, peripheral artery disease, or cerebrovascular disease should use dexibuprofen with careful consideration and avoid high-dose dexibuprofen (1200 mg per day). Additionally, patients with cardiovascular risk factors (e.g. hypertension, hyperlipidemia, diabetes, smoking) who require high doses of dexibuprofen (1200 mg per day) should be carefully considered before starting long-term treatment.
Clinical studies have shown that use of high doses (2400 mg per day) of ibuprofen may slightly increase the risk of arterial thrombosis (myocardial infarction or stroke). Overall, epidemiological studies have not demonstrated an association between low doses of ibuprofen (e.g., less than 1200 mg per day) and increased risk of arterial thrombotic events. Although there are limited data on the risk of arterial thrombosis with dexibuprofen, it is reasonable to assume that the risk of high-dose dexibuprofen (1200 mg per day) is similar to that of high-dose ibuprofen (2400 mg per day).
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. The following people should not take this medicine.
1) Patients with gastrointestinal ulcers or signs of gastrointestinal ulcers, or patients with a history of recurrence
2) Patients with bleeding in the gastrointestinal tract, cerebral blood vessels, or other areas
3) Patients with severe blood abnormalities
4) Patients with severe liver impairment
5) Patients with severe renal impairment
6) Patients with severe heart failure
7) Patients with severe high blood pressure
8) Patients with hypersensitivity to this drug or its components
9) Patients with bronchial asthma or a history of it
10) Patients with a history of asthma, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactic reactions after administration of non-steroidal anti-inflammatory drugs have been rarely reported.)
11) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
12) Pregnant women over 6 months of pregnancy (Like non-steroidal anti-inflammatory drugs, this drug may cause premature closure of the fetus's ductus arteriosus when administered at the end of pregnancy.)
13) Patients with inflammatory bowel disease such as Crohn’s disease or ulcerative colitis
14) Patients with a history of gastrointestinal bleeding or perforation due to previous treatment with non-steroidal anti-inflammatory drugs
15) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Do not take the following medicines while taking this medicine.
1) Aspirin
(1) There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of NSAIDs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
(2) When administered together with aspirin, the action of this drug and other non-steroidal anti-inflammatory analgesics may be reduced.
2) When co-administered with other non-steroidal anti-inflammatory analgesics, the risk of adverse reactions such as gastrointestinal adverse reactions and gastrointestinal bleeding may increase, so do not co-administer.
3) High-dose methotrexate (more than 15 mg/week): Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, do not co-administer with high-dose methotrexate used for anticancer therapy.
4. Do not do the following while taking this medicine.
1) Since transfer to breast milk has been reported and there is concern that serious adverse reactions may occur in infants due to this, breastfeeding or drug administration should be discontinued considering the importance of drug administration.
2) When taking this drug, side effects such as dizziness or fatigue may occur and the patient's ability to respond may decrease. Therefore, you should take it with caution when driving or operating machinery. No special precautions are required when taking it once or for a short period of time.
3) Taking high doses for a long period of time may cause headaches.
5. The following people should consult a doctor, dentist, or pharmacist before taking this medicine.
1) Patients with blood abnormalities or a history of them
2) Patients with bleeding tendencies (platelet dysfunction may occur)
3) Patients with hepatic impairment or its history
4) Patients with renal impairment or its history
5) Patients with fluid retention or heart failure
6) Patients with high blood pressure
7) Patients with a history of hypersensitivity reaction
8) Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)
9) Elderly (since adverse reactions are likely to occur, start administration from a small amount and administer the minimum amount necessary, and administer carefully while observing the patient's condition, paying particular attention to the occurrence of adverse reactions.)
10) Children over 6 years of age (Safety and efficacy in children under 6 years of age have not been established. For children over 6 years of age, administer with caution in the minimum necessary dose and pay particular attention to the occurrence of adverse reactions.)
11) Stomach cancer patient
12) Alcoholism patient
13) Pregnant women in the early and middle stages of pregnancy [metabolic toxicity (suppression of the number of implantations and survival at high doses has been reported in animal experiments), and there have been reports of fetal circulatory failure (PEO) occurring with other antipyretic analgesic and anti-inflammatory drugs], women planning pregnancy (like other prostaglandin synthesis inhibitors, this drug reduces fertility. Women who have difficulty conceiving or are undergoing infertility testing should consider discontinuing this drug) ), women who may be pregnant
14) Patients with ischemic heart disease, peripheral artery disease, and cerebrovascular disease
15) Patients with risk factors for cardiovascular disease (e.g. high blood pressure, hyperlipidemia, diabetes, smoking)
16) Patients with hepatic porphyria (use of this drug may cause seizures)
17) Patients who underwent major surgical procedures that resulted in blood deficiency
18) Patients taking diuretics or ACE inhibitors
19) Patients with blood coagulation disorders or receiving anticoagulants
20) Patients who have had digestive ulcers due to past long-term administration of non-steroidal anti-inflammatory drugs, and who require long-term administration of this drug and are concurrently receiving peptic ulcer treatment with misoprostol (some peptic ulcers are resistant to treatment with misoprostol, so sufficiently observe the progress while taking this drug).
21) Patients taking the following drugs
(1) Corticosteroids, alcohol: There is a risk of gastrointestinal adverse reactions and gastrointestinal bleeding.
(2) Digoxin, phenytoin: Plasma concentration may increase.
(3) Probenecid, sulfinpyrazone: The action of propenecid and sulfinpyrazone may be reduced and the excretion of dexibuprofen may be delayed.
(4) Sulfonylurease: The blood sugar lowering effect of sulfonylurease may be increased.
(5) ACE inhibitors or angiotensin II receptor antagonists: There have been reports that the antihypertensive effect of ACE inhibitors or angiotensin II receptor antagonists may be reduced by non-steroidal anti-inflammatory drugs, so this interaction should be kept in mind when coadministering this drug with an ACE inhibitor or angiotensin II receptor antagonist.
(6) Diuretics: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidney. During concomitant administration of these drugs and nonsteroidal anti-inflammatory drugs, patients should be closely monitored for symptoms of renal impairment and signs of renal failure.
(7) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce the renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering NSAIDs and lithium, signs of lithium toxicity should be carefully observed.
(8) Coumarin anticoagulants (warfarin, etc.): Warfarin and non-steroidal anti-inflammatory painkillers may have a synergistic effect on gastrointestinal bleeding. Therefore, patients who use both drugs together may have a higher risk of severe gastrointestinal bleeding compared to those who take the drugs alone, so they should be administered carefully, such as sufficient observation and dose reduction.
(9) Baclofen: The toxicity of baclofen increases.
(10) Immunosuppressants (cyclosporine, tacrolimus, sirolimus): Nephrotoxicity of cyclosporine, tacrolimus, and sirolimus may increase when administered concurrently with nonsteroidal anti-inflammatory drugs.
(11) Thrombolytics, ticlopidine, antithrombotic agents: Dexibuprofen inhibits platelet aggregation by inhibiting COX in platelets. Therefore, there is a risk of increased antiplatelet effect when dexibuprofen is used in combination with thrombolytics, ticlopidine, and antithrombotic agents.
(12) Drugs that increase potassium concentration in the blood (e.g., potassium-retaining diuretics, ACE inhibitors, angiotensin-II receptor antagonists, immunosuppressants such as cyclosporine and tacrolimus, trimethoprim, heparin, etc.): Hyperkalemia may occur when administered together, so regular observation of potassium levels is necessary in these cases.
(13) Inducers of CYP2C8 and CYP2C9 (e.g. rifampicin, phenobarbital): May increase the metabolism of this drug and reduce its efficacy.
(14) Low dose (less than 15 mg/week) of methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs may delay the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate, so concurrent administration should be done with caution.
(15) Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): The risk of gastrointestinal bleeding may increase when used together with this drug.
(16) People taking low-dose aspirin for the purpose of preventing myocardial infarction or stroke (this drug may reduce the effect of aspirin and increase the risk of serious gastrointestinal adverse reactions).
Laboratory data have shown that when ibuprofen and aspirin (acetylsalicylic acid) are administered together, ibuprofen can competitively inhibit the platelet aggregation effect of low-dose aspirin. Several pharmacokinetic studies have shown that ibuprofen 400 mg (single dose) decreased the effect of aspirin on thromboxane formation or platelet aggregation when administered 8 hours before or 30 minutes after the immediate release of aspirin 81 mg. Although clinical uncertainty exists regarding the extrapolation of these data, the possibility that the cardioprotective effects of low-dose aspirin may be reduced with regular or long-term ibuprofen use cannot be excluded. Occasional use of ibuprofen does not appear to be of clinical relevance. Although there are no data for dexibuprofen, it is reasonable to assume that there is an interaction between dexibuprofen and low-dose aspirin similar to ibuprofen.
6. In the following cases, stop taking this medicine immediately and consult a doctor, dentist, or pharmacist. Please carry this attached document with you whenever possible during the consultation.
1) Shock: Shock symptoms may occur in rare cases, so observe thoroughly and immediately discontinue administration if symptoms such as chest discomfort, chills, difficulty breathing, or decreased blood pressure appear.
2) Blood system: In rare cases, blood disorders such as aplastic anemia, hemolytic anemia, granulocytosis, leukocytopenia, agranulosis, pancytopenia, thrombocytopenia, decreased platelet function (prolongation of bleeding time), and eosinophil multiplication may occur. Therefore, conduct sufficient observation, including blood tests, and immediately discontinue administration if any abnormalities occur.
3) Digestive system: Indigestion, abdominal distension, heartburn, pain in the upper abdomen, diarrhea or constipation, sometimes loss of appetite, nausea, vomiting, abdominal pain, stomach discomfort, or in rare cases, esophagitis, esophageal stricture, exacerbation of diverticulum, non-specific hemorrhagic colitis, ulcerative colitis or Crohn's disease, peptic ulcer gastrointestinal bleeding, perforation, bloody stool, gastritis, pancreatitis, and in very rare cases, dry mouth or stomatitis. Stop.
4) Skin: Erythema multiforme, systemic lupus erythematosus (SLE), hair loss, sometimes angioedema, rarely mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome) and toxic epidermal necrolysis (Riel syndrome), drug rash with unknown eosinophilia and systemic syndrome (DRESS syndrome), and acute generalized erythematous pustulosis (AGEP) may occur. In these cases, discontinue administration.
5) Hypersensitivity reaction: Occasionally, rash, hives, itching, purpura, rare asthma attack, eczema, anaphylactic reaction, or photosensitivity reaction may occur. In such cases, discontinue administration.
6) Liver: Rarely jaundice, elevated ALT, elevated AST, elevated ALP, abnormal liver function, hepatitis, jaundice, etc.
7) Respiratory system: Sometimes rhinitis, bronchospasm, and rarely, in patients with heart failure, risk of acute pneumonia.
8) Sensory system: In rare cases, visual impairment such as ignoring or darkening may occur. In such cases, discontinue administration. Additionally, in rare cases, hearing loss, tinnitus, and taste abnormalities may occur.
9) Mental nervous system: Fatigue, drowsiness, headache, dizziness, sometimes anxiety, restlessness, confusion, depression, and rarely aseptic meningitis have been reported. If symptoms such as severe headache, nausea, vomiting, insomnia, stiff neck, fever, or impaired consciousness appear, immediately discontinue administration and consult a doctor. In particular, patients with autoimmune diseases (systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)) should take with caution. Additionally, in rare cases, psychosis, agitation, excitement, disorientation, and reversible toxic amblyopia may occur.
10) Circulatory system: Rarely decreased blood pressure, increased blood pressure, palpitations, etc.
11) Kidney: In rare cases, it may cause acute renal failure, so if symptoms such as oliguria or hematuria, elevated urine protein, BUN, or blood creatinine, or hyperkalemia appear in the test results, stop administration and take appropriate measures. Additionally, decreased urine volume, systemic edema and accompanying shortness of breath, drowsiness, and rarely renal papillary necrosis, nephrotic syndrome, and interstitial nephritis may occur.
12) Cardiovascular system: Peripheral edema may occur, and in patients with heart failure, the risk of acute pulmonary edema may increase. Additionally, patients with high blood pressure or renal failure may experience fluid retention. High blood pressure or heart failure may occur, especially in elderly people.
13) Endocrine system: Decreased fertility in women
14) Others: Occasionally periorbital edema, and very rarely, malaise, fever, nosebleeds, worsening inflammation, etc.
7. Other precautions when taking this drug
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using for chronic diseases, consider the following.
(1) Patients taking this drug for a long period of time should regularly conduct clinical tests (blood tests such as urinalysis, complete blood count (CBC) and physicochemical tests, liver function tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping medication. If necessary, a blood coagulation test (when anticoagulants are administered), a blood potassium concentration test (when a potassium retaining agent is administered), or a blood lithium concentration test is regularly performed. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
(2) Treatments other than drug therapy are also considered.
4) When using for acute diseases, consider the following:
(1) Administer considering the degree of acute inflammation, pain, and fever.
(2) In principle, long-term administration of the same drug should be avoided.
(3) If there is a causal treatment, implement it.
(4) In case of long-term administration, in principle, it is limited to 5 days.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Symptoms such as excessive decrease in body temperature, collapse, and cooling of extremities may occur, so pay close attention to the patient's condition after administration, especially in infants, children, the elderly, or patients with consumptive diseases accompanied by high fever.
6) Due to the pharmacological properties of this drug, other symptoms and signs of inflammation may be suppressed, delaying the diagnosis of infectious complications under painful and non-infectious conditions. When using this drug for inflammation caused by infection, it should be administered with caution, along with an appropriate antibacterial agent and sufficient observation.
7) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
8) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
9) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
10) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal failure, liver failure, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
11) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
12) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
13) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
14) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
15) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
16) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients.
17) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
18) Temporary infertility has been reported in women taking nonsteroidal anti-inflammatory drugs for a long time.
19) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
20) Effect on clinical laboratory values: In rare cases, increases in urea nitrogen, transaminases, and alkaline phosphatase, decreases in hemoglobin and hematocrit, decreased platelet aggregation, and prolonged bleeding time may occur.
21) Domestic post-marketing surveillance results (syrup formulation)
- The results of post-marketing surveillance conducted on 654 and 469 patients over 4 years for re-examination in Korea are as follows.
(1) As a result of a post-marketing study conducted on 654 patients, the adverse event rate was reported to be 0.61% (4 people/654 people, 4 cases) regardless of causal relationship. Fussiness, facial swelling, indigestion, and itching each occurred at 0.15% (1 person/654 people, 1 case).
The occurrence rate of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 0.46% (3 people/654 people, 3 cases), with irritability, facial edema, and indigestion each at 0.15% (1 person/654 people, 1 case). Unexpected adverse drug reactions were reported as irritability in 0.15% (1/654 people, 1 case).
Adverse events voluntarily reported during the domestic post-marketing surveillance period included one case of anaphylactic shock and one case of rash. Since these were reported from a population of uncertain size, it is difficult to estimate their frequency and causal relationship with this drug.
(2) As a result of a post-marketing survey conducted on 469 patients, the adverse event rate was reported to be 1.07% (5 patients/469 patients, 5 cases) regardless of causal relationship. Diarrhea was found to be 0.85% (4 people/469 people, 4 cases), vomiting was 0.21% (1 person/469 people, 1 case), and no adverse drug reactions were reported. Among these, no serious or unexpected adverse events were reported.
8. Administration to pregnant women
1) Use of non-steroidal anti-inflammatory drugs (NSAIDs), including this drug, after approximately 20 weeks of pregnancy may cause abnormalities in fetal renal function, resulting in oligohydramnios and, in some cases, neonatal renal failure. Although oligohydramnios has been uncommonly reported within 48 hours of starting nonsteroidal anti-inflammatory drugs (NSAIDs), this side effect usually appears days to weeks after administration. Oligohydramnios is usually reversible upon discontinuation of treatment, but this is not always the case. If oligohydramnios persists, complications (e.g., limb contractures and delayed lung maturation) may occur. Some post-marketing cases of impaired neonatal renal function have required invasive procedures such as exchange transfusion or dialysis. If administration of this drug is necessary during the 20th to 30th week of pregnancy, the lowest effective dose should be used for the shortest period of time and if the administration time exceeds 48 hours, ultrasound monitoring of amniotic fluid should be considered. If oligohydramnios occurs, discontinue this drug and follow-up according to medical guidelines.
9. Treatment in case of overdose
In case of overdose of this medicine, you should seek medical attention promptly even if there are no obvious symptoms or signs (quickly perform a stomach lavage or drink water to dilute. If within 60 minutes of ingestion, vomiting may be attempted).
10. Storage precautions
1) Keep out of reach of children.
2) Avoid direct sunlight and, if possible, store in a cool place with low humidity with the lid tightly closed.
3) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
11. Information for experts
A. In a 2 × 2 crossover study, healthy adults received a single oral dose of one tablet each of the test product, Dexidifen 400 mg tablets (dexibuprofen D.C.; KyungDong Pharm Co., Ltd.), and the reference product, Dibuprofen 400 mg tablets (dexibuprofen D.C.; Unimed Pharm Inc.), under fasting conditions. Plasma dexibuprofen concentrations were measured in 27 participants. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating bioequivalence.
* Table: Refer to attached document
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredient: Dexibuprofen D.C. (in-house specification) --- 400mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Stearic acid, Opadry IIAMB White (88A180040), Opadry White (03B28796), low-substituted hydroxypropyl cellulose, colloidal silicon oxide
2. Effectiveness
1. Chronic polyarthritis, rheumatoid arthritis
2. Arthropathy
3. Ankylosing spondylitis
4. Painful swelling or inflammation after trauma or surgery
5. Aid in the treatment of infections accompanied by inflammation, pain, and fever
3. Dosage and dosage
Adults: Orally administer 400 mg at a time as dexibuprofen, 2 to 3 times a day.
However, the daily dose of dexibuprofen should not exceed 1,200 mg.
4. Precautions for use
1. Warning
1) If a person who regularly drinks more than 3 cups of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about the signs and/or symptoms of serious cardiovascular toxicity and the measures to be taken if these symptoms occur.
Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischemic heart disease, peripheral artery disease, or cerebrovascular disease should use dexibuprofen with careful consideration and avoid high-dose dexibuprofen (1200 mg per day). Additionally, patients with cardiovascular risk factors (e.g. hypertension, hyperlipidemia, diabetes, smoking) who require high doses of dexibuprofen (1200 mg per day) should be carefully considered before starting long-term treatment.
Clinical studies have shown that use of high doses (2400 mg per day) of ibuprofen may slightly increase the risk of arterial thrombosis (myocardial infarction or stroke). Overall, epidemiological studies have not demonstrated an association between low doses of ibuprofen (e.g., less than 1200 mg per day) and increased risk of arterial thrombotic events. Although there are limited data on the risk of arterial thrombosis with dexibuprofen, it is reasonable to assume that the risk of high-dose dexibuprofen (1200 mg per day) is similar to that of high-dose ibuprofen (2400 mg per day).
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. The following people should not take this medicine.
1) Patients with gastrointestinal ulcers or signs of gastrointestinal ulcers, or patients with a history of recurrence
2) Patients with bleeding in the gastrointestinal tract, cerebral blood vessels, or other areas
3) Patients with severe blood abnormalities
4) Patients with severe liver impairment
5) Patients with severe renal impairment
6) Patients with severe heart failure
7) Patients with severe high blood pressure
8) Patients with hypersensitivity to this drug or its components
9) Patients with bronchial asthma or a history of it
10) Patients with a history of asthma, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactic reactions after administration of non-steroidal anti-inflammatory drugs have been rarely reported.)
11) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
12) Pregnant women over 6 months of pregnancy (Like non-steroidal anti-inflammatory drugs, this drug may cause premature closure of the fetus's ductus arteriosus when administered at the end of pregnancy.)
13) Patients with inflammatory bowel disease such as Crohn’s disease or ulcerative colitis
14) Patients with a history of gastrointestinal bleeding or perforation due to previous treatment with non-steroidal anti-inflammatory drugs
15) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Do not take the following medicines while taking this medicine.
1) Aspirin
(1) There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic events associated with the use of NSAIDs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
(2) When administered together with aspirin, the action of this drug and other non-steroidal anti-inflammatory analgesics may be reduced.
2) When co-administered with other non-steroidal anti-inflammatory analgesics, the risk of adverse reactions such as gastrointestinal adverse reactions and gastrointestinal bleeding may increase, so do not co-administer.
3) High-dose methotrexate (more than 15 mg/week): Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, do not co-administer with high-dose methotrexate used for anticancer therapy.
4. Do not do the following while taking this medicine.
1) Since transfer to breast milk has been reported and there is concern that serious adverse reactions may occur in infants due to this, breastfeeding or drug administration should be discontinued considering the importance of drug administration.
2) When taking this drug, side effects such as dizziness or fatigue may occur and the patient's ability to respond may decrease. Therefore, you should take it with caution when driving or operating machinery. No special precautions are required when taking it once or for a short period of time.
3) Taking high doses for a long period of time may cause headaches.
5. The following people should consult a doctor, dentist, or pharmacist before taking this medicine.
1) Patients with blood abnormalities or a history of them
2) Patients with bleeding tendencies (platelet dysfunction may occur)
3) Patients with hepatic impairment or its history
4) Patients with renal impairment or its history
5) Patients with fluid retention or heart failure
6) Patients with high blood pressure
7) Patients with a history of hypersensitivity reaction
8) Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)
9) Elderly (since adverse reactions are likely to occur, start administration from a small amount and administer the minimum amount necessary, and administer carefully while observing the patient's condition, paying particular attention to the occurrence of adverse reactions.)
10) Children over 6 years of age (Safety and efficacy in children under 6 years of age have not been established. For children over 6 years of age, administer with caution in the minimum necessary dose and pay particular attention to the occurrence of adverse reactions.)
11) Stomach cancer patient
12) Alcoholism patient
13) Pregnant women in the early and middle stages of pregnancy [metabolic toxicity (suppression of the number of implantations and survival at high doses has been reported in animal experiments), and there have been reports of fetal circulatory failure (PEO) occurring with other antipyretic analgesic and anti-inflammatory drugs], women planning pregnancy (like other prostaglandin synthesis inhibitors, this drug reduces fertility. Women who have difficulty conceiving or are undergoing infertility testing should consider discontinuing this drug) ), women who may be pregnant
14) Patients with ischemic heart disease, peripheral artery disease, and cerebrovascular disease
15) Patients with risk factors for cardiovascular disease (e.g. high blood pressure, hyperlipidemia, diabetes, smoking)
16) Patients with hepatic porphyria (use of this drug may cause seizures)
17) Patients who underwent major surgical procedures that resulted in blood deficiency
18) Patients taking diuretics or ACE inhibitors
19) Patients with blood coagulation disorders or receiving anticoagulants
20) Patients who have had digestive ulcers due to past long-term administration of non-steroidal anti-inflammatory drugs, and who require long-term administration of this drug and are concurrently receiving peptic ulcer treatment with misoprostol (some peptic ulcers are resistant to treatment with misoprostol, so sufficiently observe the progress while taking this drug).
21) Patients taking the following drugs
(1) Corticosteroids, alcohol: There is a risk of gastrointestinal adverse reactions and gastrointestinal bleeding.
(2) Digoxin, phenytoin: Plasma concentration may increase.
(3) Probenecid, sulfinpyrazone: The action of propenecid and sulfinpyrazone may be reduced and the excretion of dexibuprofen may be delayed.
(4) Sulfonylurease: The blood sugar lowering effect of sulfonylurease may be increased.
(5) ACE inhibitors or angiotensin II receptor antagonists: There have been reports that the antihypertensive effect of ACE inhibitors or angiotensin II receptor antagonists may be reduced by non-steroidal anti-inflammatory drugs, so this interaction should be kept in mind when coadministering this drug with an ACE inhibitor or angiotensin II receptor antagonist.
(6) Diuretics: Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidney. During concomitant administration of these drugs and nonsteroidal anti-inflammatory drugs, patients should be closely monitored for symptoms of renal impairment and signs of renal failure.
(7) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce the renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering NSAIDs and lithium, signs of lithium toxicity should be carefully observed.
(8) Coumarin anticoagulants (warfarin, etc.): Warfarin and non-steroidal anti-inflammatory painkillers may have a synergistic effect on gastrointestinal bleeding. Therefore, patients who use both drugs together may have a higher risk of severe gastrointestinal bleeding compared to those who take the drugs alone, so they should be administered carefully, such as sufficient observation and dose reduction.
(9) Baclofen: The toxicity of baclofen increases.
(10) Immunosuppressants (cyclosporine, tacrolimus, sirolimus): Nephrotoxicity of cyclosporine, tacrolimus, and sirolimus may increase when administered concurrently with nonsteroidal anti-inflammatory drugs.
(11) Thrombolytics, ticlopidine, antithrombotic agents: Dexibuprofen inhibits platelet aggregation by inhibiting COX in platelets. Therefore, there is a risk of increased antiplatelet effect when dexibuprofen is used in combination with thrombolytics, ticlopidine, and antithrombotic agents.
(12) Drugs that increase potassium concentration in the blood (e.g., potassium-retaining diuretics, ACE inhibitors, angiotensin-II receptor antagonists, immunosuppressants such as cyclosporine and tacrolimus, trimethoprim, heparin, etc.): Hyperkalemia may occur when administered together, so regular observation of potassium levels is necessary in these cases.
(13) Inducers of CYP2C8 and CYP2C9 (e.g. rifampicin, phenobarbital): May increase the metabolism of this drug and reduce its efficacy.
(14) Low dose (less than 15 mg/week) of methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs may delay the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate, so concurrent administration should be done with caution.
(15) Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): The risk of gastrointestinal bleeding may increase when used together with this drug.
(16) People taking low-dose aspirin for the purpose of preventing myocardial infarction or stroke (this drug may reduce the effect of aspirin and increase the risk of serious gastrointestinal adverse reactions).
Laboratory data have shown that when ibuprofen and aspirin (acetylsalicylic acid) are administered together, ibuprofen can competitively inhibit the platelet aggregation effect of low-dose aspirin. Several pharmacokinetic studies have shown that ibuprofen 400 mg (single dose) decreased the effect of aspirin on thromboxane formation or platelet aggregation when administered 8 hours before or 30 minutes after the immediate release of aspirin 81 mg. Although clinical uncertainty exists regarding the extrapolation of these data, the possibility that the cardioprotective effects of low-dose aspirin may be reduced with regular or long-term ibuprofen use cannot be excluded. Occasional use of ibuprofen does not appear to be of clinical relevance. Although there are no data for dexibuprofen, it is reasonable to assume that there is an interaction between dexibuprofen and low-dose aspirin similar to ibuprofen.
6. In the following cases, stop taking this medicine immediately and consult a doctor, dentist, or pharmacist. Please carry this attached document with you whenever possible during the consultation.
1) Shock: Shock symptoms may occur in rare cases, so observe thoroughly and immediately discontinue administration if symptoms such as chest discomfort, chills, difficulty breathing, or decreased blood pressure appear.
2) Blood system: In rare cases, blood disorders such as aplastic anemia, hemolytic anemia, granulocytosis, leukocytopenia, agranulosis, pancytopenia, thrombocytopenia, decreased platelet function (prolongation of bleeding time), and eosinophil multiplication may occur. Therefore, conduct sufficient observation, including blood tests, and immediately discontinue administration if any abnormalities occur.
3) Digestive system: Indigestion, abdominal distension, heartburn, pain in the upper abdomen, diarrhea or constipation, sometimes loss of appetite, nausea, vomiting, abdominal pain, stomach discomfort, or in rare cases, esophagitis, esophageal stricture, exacerbation of diverticulum, non-specific hemorrhagic colitis, ulcerative colitis or Crohn's disease, peptic ulcer gastrointestinal bleeding, perforation, bloody stool, gastritis, pancreatitis, and in very rare cases, dry mouth or stomatitis. Stop.
4) Skin: Erythema multiforme, systemic lupus erythematosus (SLE), hair loss, sometimes angioedema, rarely mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome) and toxic epidermal necrolysis (Riel syndrome), drug rash with unknown eosinophilia and systemic syndrome (DRESS syndrome), and acute generalized erythematous pustulosis (AGEP) may occur. In these cases, discontinue administration.
5) Hypersensitivity reaction: Occasionally, rash, hives, itching, purpura, rare asthma attack, eczema, anaphylactic reaction, or photosensitivity reaction may occur. In such cases, discontinue administration.
6) Liver: Rarely jaundice, elevated ALT, elevated AST, elevated ALP, abnormal liver function, hepatitis, jaundice, etc.
7) Respiratory system: Sometimes rhinitis, bronchospasm, and rarely, in patients with heart failure, risk of acute pneumonia.
8) Sensory system: In rare cases, visual impairment such as ignoring or darkening may occur. In such cases, discontinue administration. Additionally, in rare cases, hearing loss, tinnitus, and taste abnormalities may occur.
9) Mental nervous system: Fatigue, drowsiness, headache, dizziness, sometimes anxiety, restlessness, confusion, depression, and rarely aseptic meningitis have been reported. If symptoms such as severe headache, nausea, vomiting, insomnia, stiff neck, fever, or impaired consciousness appear, immediately discontinue administration and consult a doctor. In particular, patients with autoimmune diseases (systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)) should take with caution. Additionally, in rare cases, psychosis, agitation, excitement, disorientation, and reversible toxic amblyopia may occur.
10) Circulatory system: Rarely decreased blood pressure, increased blood pressure, palpitations, etc.
11) Kidney: In rare cases, it may cause acute renal failure, so if symptoms such as oliguria or hematuria, elevated urine protein, BUN, or blood creatinine, or hyperkalemia appear in the test results, stop administration and take appropriate measures. Additionally, decreased urine volume, systemic edema and accompanying shortness of breath, drowsiness, and rarely renal papillary necrosis, nephrotic syndrome, and interstitial nephritis may occur.
12) Cardiovascular system: Peripheral edema may occur, and in patients with heart failure, the risk of acute pulmonary edema may increase. Additionally, patients with high blood pressure or renal failure may experience fluid retention. High blood pressure or heart failure may occur, especially in elderly people.
13) Endocrine system: Decreased fertility in women
14) Others: Occasionally periorbital edema, and very rarely, malaise, fever, nosebleeds, worsening inflammation, etc.
7. Other precautions when taking this drug
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
3) When using for chronic diseases, consider the following.
(1) Patients taking this drug for a long period of time should regularly conduct clinical tests (blood tests such as urinalysis, complete blood count (CBC) and physicochemical tests, liver function tests, etc.), and if abnormalities are found, take appropriate measures such as reducing the dose or stopping medication. If necessary, a blood coagulation test (when anticoagulants are administered), a blood potassium concentration test (when a potassium retaining agent is administered), or a blood lithium concentration test is regularly performed. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
(2) Treatments other than drug therapy are also considered.
4) When using for acute diseases, consider the following:
(1) Administer considering the degree of acute inflammation, pain, and fever.
(2) In principle, long-term administration of the same drug should be avoided.
(3) If there is a causal treatment, implement it.
(4) In case of long-term administration, in principle, it is limited to 5 days.
5) Observe the patient's condition sufficiently and pay attention to the occurrence of adverse reactions. Symptoms such as excessive decrease in body temperature, collapse, and cooling of extremities may occur, so pay close attention to the patient's condition after administration, especially in infants, children, the elderly, or patients with consumptive diseases accompanied by high fever.
6) Due to the pharmacological properties of this drug, other symptoms and signs of inflammation may be suppressed, delaying the diagnosis of infectious complications under painful and non-infectious conditions. When using this drug for inflammation caused by infection, it should be administered with caution, along with an appropriate antibacterial agent and sufficient observation.
7) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
8) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
9) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
10) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal failure, liver failure, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
11) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
12) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
13) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
14) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
15) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
16) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients.
17) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
18) Temporary infertility has been reported in women taking nonsteroidal anti-inflammatory drugs for a long time.
19) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
20) Effect on clinical laboratory values: In rare cases, increases in urea nitrogen, transaminases, and alkaline phosphatase, decreases in hemoglobin and hematocrit, decreased platelet aggregation, and prolonged bleeding time may occur.
21) Domestic post-marketing surveillance results (syrup formulation)
- The results of post-marketing surveillance conducted on 654 and 469 patients over 4 years for re-examination in Korea are as follows.
(1) As a result of a post-marketing study conducted on 654 patients, the adverse event rate was reported to be 0.61% (4 people/654 people, 4 cases) regardless of causal relationship. Fussiness, facial swelling, indigestion, and itching each occurred at 0.15% (1 person/654 people, 1 case).
The occurrence rate of adverse drug reactions for which a causal relationship with this drug cannot be ruled out was 0.46% (3 people/654 people, 3 cases), with irritability, facial edema, and indigestion each at 0.15% (1 person/654 people, 1 case). Unexpected adverse drug reactions were reported as irritability in 0.15% (1/654 people, 1 case).
Adverse events voluntarily reported during the domestic post-marketing surveillance period included one case of anaphylactic shock and one case of rash. Since these were reported from a population of uncertain size, it is difficult to estimate their frequency and causal relationship with this drug.
(2) As a result of a post-marketing survey conducted on 469 patients, the adverse event rate was reported to be 1.07% (5 patients/469 patients, 5 cases) regardless of causal relationship. Diarrhea was found to be 0.85% (4 people/469 people, 4 cases), vomiting was 0.21% (1 person/469 people, 1 case), and no adverse drug reactions were reported. Among these, no serious or unexpected adverse events were reported.
8. Administration to pregnant women
1) Use of non-steroidal anti-inflammatory drugs (NSAIDs), including this drug, after approximately 20 weeks of pregnancy may cause abnormalities in fetal renal function, resulting in oligohydramnios and, in some cases, neonatal renal failure. Although oligohydramnios has been uncommonly reported within 48 hours of starting nonsteroidal anti-inflammatory drugs (NSAIDs), this side effect usually appears days to weeks after administration. Oligohydramnios is usually reversible upon discontinuation of treatment, but this is not always the case. If oligohydramnios persists, complications (e.g., limb contractures and delayed lung maturation) may occur. Some post-marketing cases of impaired neonatal renal function have required invasive procedures such as exchange transfusion or dialysis. If administration of this drug is necessary during the 20th to 30th week of pregnancy, the lowest effective dose should be used for the shortest period of time and if the administration time exceeds 48 hours, ultrasound monitoring of amniotic fluid should be considered. If oligohydramnios occurs, discontinue this drug and follow-up according to medical guidelines.
9. Treatment in case of overdose
In case of overdose of this medicine, you should seek medical attention promptly even if there are no obvious symptoms or signs (quickly perform a stomach lavage or drink water to dilute. If within 60 minutes of ingestion, vomiting may be attempted).
10. Storage precautions
1) Keep out of reach of children.
2) Avoid direct sunlight and, if possible, store in a cool place with low humidity with the lid tightly closed.
3) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
11. Information for experts
A. In a 2 × 2 crossover study, healthy adults received a single oral dose of one tablet each of the test product, Dexidifen 400 mg tablets (dexibuprofen D.C.; KyungDong Pharm Co., Ltd.), and the reference product, Dibuprofen 400 mg tablets (dexibuprofen D.C.; Unimed Pharm Inc.), under fasting conditions. Plasma dexibuprofen concentrations were measured in 27 participants. Statistical analysis of log-transformed AUCt and Cmax values showed that the 90% confidence intervals for the differences in means were within log 0.8 to log 1.25, demonstrating bioequivalence.
* Table: Refer to attached document
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 4items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 4 | Dexidifen Tab. 400mg | Precautions for use | 2026.01.02 | PDF0082_201602338_Dexidifen Tablet 400mg_Precautions for use.pdf |
| 3 | Dexidifen Tab. 400mg | Precautions for use | 2025.03.18 | PDF0084_201602338_Precautions for use_Dexidifen tablet 400mg.pdf |
| 2 | Dexidifen Tab. 400mg | Precautions for use | 2024.05.22 | PDFDexidifen Tablet 400mg_Precautions for use.pdf |
| 1 | Dexidifen Tab. 400mg | Precautions for use | 2023.10.02 | PDF0096_201602338_Precautions for use (Dexidifen tablets 400mg).pdf |